MAP2K7 and cancer: In clinical therapy, vemurafenib exhibited an exceptional efficacy with manageable side effects on cancers with BRAF(V600E) mutation as a single agent or combined with cobimetinib (MEK inhibitor), although drug resistance occurs after 6-8 months of administration.